ライフサイエンスコーパス: EGCG

1 EGCG administration blunted self DNA-induced autoinflamm

2 EGCG antagonized the ConA-induced CSF-2 and CSF-3 gene e

3 EGCG application by zonal priming significantly down-reg

4 EGCG could attenuate Pg LPS-enhanced production of MMP-1

5 EGCG inhibits the ability of preformed oligomers to perm

6 EGCG normalized the palmitate-induced impairment of auto

7 EGCG protons were mapped to the protein surface by trian

8 EGCG reached maximum inhibition of HSA and PPA with shor

9 EGCG reduced mast cells at weeks 1-3, as evidenced by ge

10 EGCG reduced the amyloid-specific fluorescent thioflavin

11 EGCG specifically inhibited the second aggregation phase

12 EGCG was found to be more efficient than EC as inhibitor

13 EGCG was shown in transmission electron microscopy (TEM)

14 EGCG's poor stability and intestinal permeability, howev

15 EGCG+RES supplementation did not affect the fasting plas

16 EGCG+RES supplementation significantly increased oxidati

17 EGCG, as a chain breaker, produced fewer procyanidin oli

18 EGCG, GA and caffeine were resolved with Rf values 0.54,

19 EGCG, gallic acid, and curcumin were identified as a mul

20 ric flavan-3-ol esterified with gallic acid (EGCG) had a five to ten times higher affinity to caseins

21 sed MMP-1 production in HGFs, whereas adding EGCG significantly attenuated this enhanced production o

22 After EGCG, there was a shift to a higher and more stable CHOx

23 ng exercise, postprandial EE was lower after EGCG than after placebo, indicating an increased working

24 Although EGCG treatment of hepatocytes alone had little effect on

25 regulation of EC functions implying that an EGCG dependent activation of these phosphatases leads to

26 ded greater peroxide scavenging activity and EGCG stability.

27 sion complexes with starch, with GA, CAT and EGCG in decreasing order of protection.

28 However, EGCG, empty NPs and EGCG/AA NPs all induced tight junction disruption and op

29 occurring in both Abeta(1-40) oligomers and EGCG during remodeling offer a foundation for understand

30 's disease, especially for Down syndrome and EGCG which inhibits Dyrk1A may have potential effect on

31 However, our present study shows that TA and EGCG do not inhibit the phospholipid-scrambling or ion c

32 Instead, we found that TA and EGCG mainly acted as fluorescence quenchers that rapidly

33 nstrate the false positive effects of TA and EGCG on inhibiting TMEM16F phospholipid scrambling and d

34 ggests that diet-derived polyphenols such as EGCG may exert chemopreventive action through pharmacolo

35 We assessed EGCG application compared with placebo over 1-6 weeks in

36 ish structure-activity relationships between EGCG and Hsp90.

37 nstrated the utility of the bioflavonoid (-)-EGCG, a natural product as a chiral solvating agent for

38 Both EGCG and its esterified derivatives were incorporated in

39 on might be due to the inhibition of IL-6 by EGCG.

40 oxidation was not significantly affected by EGCG+RES (P-EGCG+RES = 0.46 and 0.38, respectively) but

41 of this aggregation of HMGB1 facilitated by EGCG.

42 with degradation of Abeta fibril induced by EGCG and inhibition of Abeta fibril and oligomer formati

43 we conclude that the conformation induced by EGCG is more aggregation-prone with higher binding free

44 quires MT1-MMP signaling and is inhibited by EGCG.

45 jority of the amyloid remodeling observed by EGCG treatment, although how EGCG oxidation drives remod

46 roplets by palmitate was markedly reduced by EGCG.

47 Existing fibrils are remodeled by EGCG into non-amyloid aggregates.

48 ajor driving force for amyloid remodeling by EGCG treatment.

49 GB1, are repositioned and packed together by EGCG.

50 The multiple-ring compounds, EGCG, resveratrol, and curcumin, redirect Abeta(17-36) f

51 Consumption of green tea extracts containing EGCG improved some cognitive and behavioral outcomes in

52 Daily EGCG gavage treatments over three weeks resulted in grow

53 Direct EGCG application also reduced scar thickness at weeks 1-

54 ficial role of both zonal priming and direct EGCG application in scar therapy with positive effects o

55 Here, we dissect EGCG's mechanism of action.

56 underscore the need for caution in high-dose EGCG supplements as an intervention in DS.

57 a dynamic region of the protein that enables EGCG to control opening and closure of the enzyme's acti

58 "EGCG in the O phase" emulsion > "esterified EGCG in the W1 phase" emulsion.

59 Finally, EGCG+RES had no effect on insulin-stimulated glucose dis

60 s of Abeta(17-36) aggregation is as follows: EGCG > resveratrol > curcumin > vanillin, consistent wit

61 ify its biofilm and strengthens the case for EGCG as a candidate in multidrug treatment of persistent

62 with multiple independent binding sites for EGCG with a Kd approximately 10-fold lower than that for

63 Numerous molecular targets for EGCG have been proposed, but the mechanisms of its antic

64 ivity in PCa cell lines compared to the free EGCG.

65 ompact peptide conformations than those from EGCG-untreated Abeta species; and (ii) ternary EGCG-meta

66 Furthermore, EGCG resulted in reduced cortical bone structure and str

67 Furthermore, EGCG+RES supplementation attenuated the increase in plas

68 Furthermore, EGCG-mediated inhibition of G3BP1 provides a potential t

69 red by sugars to epigallocatechin-3-gallate (EGCG) against deterioration.

70 in (EGC) and (-)-epigallocatechin-3-gallate (EGCG) and butylated hydroxytoluene (BHT) correlate with

71 egation, such as epigallocatechin-3-gallate (EGCG) and dopamine (DA).

72 chins such as (-)epigallocatechin-3-gallate (EGCG) are known to improve energy metabolism at rest and

73 d polyphenol (-)-epigallocatechin-3-gallate (EGCG) has been extensively studied for its antioxidant a

74 nicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) and sulforaphane (

75 Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's diseas

76 Epigallocatechin-3-gallate (EGCG) is a candidate therapeutic for Down syndrome (DS)

77 e the polyphenol epigallocatechin-3-gallate (EGCG) is emerging as an experimental secondary treatment

78 een tea catechin epigallocatechin-3-gallate (EGCG) is generally considered to be the biologically mos

79 Epigallocatechin-3-gallate (EGCG) is the major polyphenol in green tea.

80 Epigallocatechin-3-gallate (EGCG) is the most biologically potent polyphenol of gree

81 l, curcumin, and epigallocatechin-3-gallate (EGCG) on the aggregation of Abeta(17-36) peptides.

82 nd influence (-)-epigallocatechin-3-gallate (EGCG) oxidation (400muM) in Tween- or sodium dodecyl sul

83 In contrast, epigallocatechin-3-gallate (EGCG) signals ECs via the 67 kDa laminin-receptor (67LR)

84 n green tea, (-)-epigallocatechin-3-gallate (EGCG)'s potential benefits to human health have been wid

85 o treatment with Epigallocatechin-3-gallate (EGCG), a Dyrk1a inhibitor, modulated trisomic NCC defici

86 have shown that epigallocatechin-3-gallate (EGCG), a major constituent of green tea extract, exhibit

87 (-)-Epigallocatechin-3-gallate (EGCG), a major polyphenol component of green tea, has re

88 Epigallocatechin-3-gallate (EGCG), a polyphenol, influences cutaneous wound healing

89 ly attributed to epigallocatechin-3-gallate (EGCG), a polyphenolic compound from the group of catechi

90 njected with (-)-epigallocatechin-3-gallate (EGCG), a redox-active polyphenol from green tea, for 32

91 polyphenol, (-)-epigallocatechin-3-gallate (EGCG), and matrix pH (2-7) on the net anti-/pro-oxidant

92 n tea catechin, epigallo-catechin 3-gallate (EGCG), and the major dietary protein and allergen, ovalb

93 interactions of epigallocatechin-3-gallate (EGCG), found in green tea, with Abeta polypeptides, usin

94 -type catechins (epigallocatechin-3-gallate (EGCG), gallocatechin-3-gallate (GCG), and epicatechin-3-

95 s, FK506 and (-)-epigallocatechin-3-gallate (EGCG), known to inhibit alphaSYN fibril formation, was i

96 itors RG108, (-) epigallocatechin-3-gallate (EGCG), or curcumin.

97 Epigallocatechin-3-gallate (EGCG), the principal polyphenol isolated from green tea,

98 Epigallocatechin-3-gallate (EGCG), the principal polyphenol present in green tea, ha

99 dopamine (DA) or epigallocatechin-3-gallate (EGCG), two inhibitors of AS aggregation, indicating that

100 tract containing epigallocatequin-3-gallate (EGCG), which improves executive function in young adults

101 polyphenol, (-)-epigallocatechin-3-gallate (EGCG).

102 in or its analogue epigallocatechin gallate (EGCG) (0.25% w/v in drinking water) was administered to

103 tisvir (DCV) 60 mg/epigallocatechin gallate (EGCG) 400 mg without ribavirin (RBV); and Dactavira plus

104 picatechin, or (-)-epigallocatechin gallate (EGCG) added as chain breakers.

105 ms contained lower epigallocatechin gallate (EGCG) and caffeine (ca. 75 and 56%, respectively) compar

106 gallate (PG), (-)-epigallocatechin gallate (EGCG) and quercetin (Q).

107 phenolic compounds epigallocatechin gallate (EGCG) and silibinin bind to specific conformers within a

108 he G3BP1 inhibitor epigallocatechin gallate (EGCG) disrupted existing G3BP1-cGAS complexes and inhibi

109 (-)-Epigallocatechin gallate (EGCG) effectively reduces the cytotoxicity of the Alzhei

110 The flavonoid epigallocatechin gallate (EGCG) has previously been shown to redirect the aggregat

111 n tea catechin and epigallocatechin gallate (EGCG) in soy lecithin liposomes was examined at four con

112 picatechin (EC) or epigallocatechin gallate (EGCG) inhibited formation of highly reactive intermediar

113 Epigallocatechin gallate (EGCG) is a major polyphenol in green tea that has benefi

114 Epigallocatechin gallate (EGCG) is a powerful antioxidant and commonly used nutrac

115 ementation high in epigallocatechin gallate (EGCG) on blood lipids in healthy postmenopausal women.

116 a shoot (GL) while epigallocatechin gallate (EGCG) recorded higher levels in GL.

117 ioxidant activity, Epigallocatechin Gallate (EGCG) was esterified with stearic acid.

118 echins, especially epigallocatechin gallate (EGCG) were found in green teas.

119 nnic acid (TA) and epigallocatechin gallate (EGCG) were recently reported as promising TMEM16F CaPLSa

120 Epigallocatechin gallate (EGCG), a major form of tea catechins, possesses immunomo

121 ine, curcumin, (-)-epigallocatechin gallate (EGCG), gallic acid, propyl gallate, resveratrol, and alp

122 chin (EGC) and (-)-epigallocatechin gallate (EGCG), respectively.

123 chin (EGC) and (-)-epigallocatechin gallate (EGCG), respectively.

124 n-3-ol substrates, epigallocatechin gallate (EGCG), was employed.

125 sfully synthesized epigallocatechin gallate (EGCG)-loaded nanoparticles (Enano), which were composed

126 f SULT1A1 bound to epigallocatechin gallate (EGCG).

127 green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau exp

128 hypothesized that epigallocatechin-gallate (EGCG), the main catechin present in green tea, forms com

129 (-)-Epigallocatechin-3-O-gallate (EGCG), a major ingredient of green tea, has been shown,

130 green tea, (-)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and ther

131 A, catechin-CAT and epigallocatechin gallate-EGCG) from processed and digested porridges with differe

132 wed by complexation of poly(ethylene glycol)-EGCG to form the shell.

133 llated catechins the most potent: CG > ECG > EGCG >= GCG when compared to the non-gallated catechins

134 the order "EGCG in the W1 phase" emulsion > "EGCG in the O phase" emulsion > "esterified EGCG in the

135 ing observed by EGCG treatment, although how EGCG oxidation drives remodeling remains unclear.

136 ng, and electron microscopy to elucidate how EGCG remodels Abeta oligomers.

137 However, EGCG does not affect oligomer size distribution or secon

138 However, EGCG, empty NPs and EGCG/AA NPs all induced tight juncti

139 These studies indicated that (i) EGCG was bound to Abeta monomers and dimers, generating

140 ase, the larger number of rotatable bonds in EGCG might be accountable for this difference.

141 We used a green tea extract enriched in EGCG to inhibit DYRK1A function only during gestation of

142 Results showed significant reduction in EGCG content after one, three and six months: 24.00%, 28

143 istration of EGCG/AA NPs in mice resulted in EGCG accumulation in all major organs, including the bra

144 The incorporated EGCG interferes with the viral entry mechanisms, as repo

145 Ps showed that, whilst in both cases initial EGCG concentrations were similar, long-term (5-25 h) con

146 the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAbeta3W, the

147 the ability of Fap to form fibrils; instead, EGCG stabilizes protein oligomers.

148 Liver EGCG content was decreased by treatments in the order of

149 ed and validated for determination of % loss EGCG.

150 plement containing 1315 mg catechins (843 mg EGCG) on biomarkers of breast cancer risk.

151 Moreover, EGCG+RES reduced fasting (P-time x treatment = 0.03) and

152 ons were detected in samples with 25-500 muM EGCG at 24h.

153 al-drug loaded PEGylated PLGA nanoparticles (EGCG/AA NPs).

154 Native EGCG had inhibitory effects on liver and body fat accumu

155 ect molecular explanation for the ability of EGCG to disrupt P. aeruginosa QS and modify its biofilm

156 These findings indicate that the ability of EGCG to inhibit myeloperoxidase activity is one of the m

157 The ability of EGCG to mediate its inhibitory activity is counter-regul

158 nomer-protofibril contacts in the absence of EGCG, undergo a direct-to-tethered contact shift.

159 lipid accumulation, suggesting the action of EGCG is through autophagosomal degradation.

160 ts into the molecular mechanism of action of EGCG provide boundary conditions for exploring amyloid r

161 -7) on the net anti-/pro-oxidant activity of EGCG in flaxseed oil-in-water (o/w) emulsions were syste

162 However, the addition of EGCG significantly attenuated the IL-6 expression and NF

163 Further, administration of EGCG to dextran sodium sulfate-induced colitic mice sign

164 Oral administration of EGCG/AA NPs in mice resulted in EGCG accumulation in all

165 HCV, suggesting the potential application of EGCG as a new anti-HCV agent for HCV therapy.

166 The behavior of EGCG encapsulated in NPs in modulating apoptosis and cel

167 Binding of EGCG to 2S albumins affects protein conformation, by cau

168 The binding of EGCG to casein micelles was quantified using HPLC.

169 loid fibrils that are broken upon binding of EGCG.

170 absorption and increased bioavailability of EGCG.

171 was in the range described for complexes of EGCG and other dietary proteins.

172 anoparticles (Enano), which were composed of EGCG, PC, (+) alpha-tocopherol acetate, and surfactant.

173 Though higher concentration of EGCG yielded better discrimination, the use of lower con

174 The cytotoxicities of EGCG and LPS were tested by cell viability tests.

175 veloped formulation for the oral delivery of EGCG and its potential for applications in food industry

176 wo HMGB1 monomers are linked by the dimer of EGCG.

177 The dose of EGCG was 25 mg per kg body weight.

178 ice treated with gradually elevated doses of EGCG exhibits some of the features observed in patients

179 The antimicrobial effect of EGCG against the opportunistic pathogen Pseudomonas aeru

180 phagosomal degradation opposed the effect of EGCG in ectopic lipid accumulation, suggesting the actio

181 o determine whether the beneficial effect of EGCG is mediated by a mechanism involving autophagy, the

182 more, we learn that the inhibition effect of EGCG is specific to the peptide sequence, while those of

183 resent in vitro study examines the effect of EGCG on Porphyromonas gingivalis (Pg) lipopolysaccharide

184 med to investigate the longer-term effect of EGCG+RES supplementation on metabolic profile, mitochond

185 e-induced lipid accumulation, the effects of EGCG on autophagic flux and co-localization of lipid dro

186 However, the efficacy of EGCG against gut inflammation is diminished when orally

187 ployed for sample clean-up and enrichment of EGCG over caffeine.

188 t the synthesis and biological evaluation of EGCG analogues to establish structure-activity relations

189 In this study, we evaluated the impact of EGCG treatment on the expression of colony-stimulating f

190 ional chemistry to elucidate interactions of EGCG and 2S albumins.

191 We find that the interactions of EGCG are dominated by only a few residues in the fibrils

192 Non-covalent interactions of EGCG with proteins contribute to its diverse biological

193 for understanding the molecular mechanism of EGCG as a neurotoxicity inhibitor.

194 However, the mechanism of EGCG-induced remodeling is not fully understood.

195 was decreased by treatments in the order of EGCG>Enano>L-Enano.

196 iled to support the therapeutic potential of EGCG, and the deleterious effects on growth and skeletal

197 proceeds at a slower rate in the presence of EGCG.

198 The mechanism of the interaction property of EGCG with alpha-amino acids has been understood as arisi

199 hod for evaluating the deterioration rate of EGCG using absorbance spectroscopy.

200 the distinct antiamyloidogenic reactivity of EGCG toward metal-Abeta species with a structure-based m

201 where the -OH groups of two phenyl rings of EGCG play dominant roles.

202 We previously showed the role of EGCG in scarring in ex vivo human scar models.

203 r explanation for the isozyme specificity of EGCG, which is corroborated experimentally.

204 nistically, we propose that stabilisation of EGCG in NPs complexes and a destabilized BBB led to high

205 Accelerated stability of EGCG in tablet formulations was investigated.

206 r inflammatory bowel disease with the use of EGCG treatment.

207 Twelve weeks of EGCG+RES supplementation increased mitochondrial capacit

208 is obtained by complexation of oligomerized EGCG with the anticancer protein Herceptin to form the c

209 e N-terminal residues experience an opposite EGCG-induced shift from tethered to direct contacts, exp

210 hieved from the incorporation of catechin or EGCG inside the liposome structure.

211 ) increased with the addition of catechin or EGCG.

212 ion following oral administration of free or EGCG/AA NPs showed that, whilst in both cases initial EG

213 ulation efficiency was reduced in the order "EGCG in the W1 phase" emulsion > "EGCG in the O phase" e

214 s90 and display improvement in efficacy over EGCG.

215 Oxidized EGCG molecules react with free amines within the amyloid

216 muscle fibers (P-time x treatment < 0.05, P-EGCG+RES < 0.05).

217 as not significantly affected by EGCG+RES (P-EGCG+RES = 0.46 and 0.38, respectively) but declined aft

218 effect on TLR3 and RIG-I signaling pathways, EGCG significantly enhanced HCV dsRNAs-induced the expre

219 eceived weekly tail vein injection with PBS, EGCG, void nanoparticles (Vnano), Enano, ligand-coated V

220 edium contributed to the cytotoxicity of PG, EGCG and Q to human prostate carcinoma DU-145 cells, sin

221 we extended our work and developed polymeric EGCG-encapsulated nanoparticles (NPs) targeted with smal

222 Furthermore, prenatal EGCG treatment normalized some craniofacial phenotypes,

223 140 chromosome 21 orthologs; thus, prenatal EGCG exhibits efficacy in a more complex DS model.

224 ed the hypothesis that 200 mg/kg/day of pure EGCG, given via oral gavage, would improve neurobehavior

225 In contrast, treatment with pure EGCG in DS mouse models did not improve neurobehavioral

226 Rather, EGCG immobilizes the C-terminal region and moderately re

227 All patients received EGCG (600 mg/d) and placebo over 12 wk (4-wk washout in

228 y lower in men but higher in women receiving EGCG compared with placebo.

229 The resulting EGCG encapsulating NPs led to an enhanced anti-prolifera

230 epigallocatechin-3-gallate and resveratrol (EGCG+RES) increased energy expenditure and improved the

231 Serum EGCG levels post-gavage were significantly higher in tri

232 teamine plus the antioxidant food supplement EGCG.

233 CG-untreated Abeta species; and (ii) ternary EGCG-metal-Abeta complexes were produced.

234 Herein, we demonstrate that EGCG can potently inhibit the proinflammatory enzyme mye

235 We found that EGCG displayed increased stability when formulated as du

236 No evidence was found that EGCG/AA NPs utilised a specific pathway across the blood

237 Given that EGCG has the ability to enhance HCV dsRNAs-induced intra

238 We tested the hypothesis that EGCG improves energy metabolism and substrate utilizatio

239 tated autophagic flux and further imply that EGCG may be a potential therapeutic reagent to prevent c

240 Recent experimental evidences indicate that EGCG can induce the aggregation of HMGB1 protein, a late

241 Our data indicate that EGCG given to patients with MS over 12 wk improves muscl

242 Spectral analysis indicated that EGCG prevents the peroxidase-catalyzed reaction by rever

243 nhibitors of AS aggregation, indicating that EGCG promotes the same final oxidation product as DA.

244 issue of the JCI, Kumazoe et al. report that EGCG activates 67-kDa laminin receptor (67LR), elevates

245 Our simulation results reveal that EGCG firmly binds to HMGB1 near Cys106, which supports p

246 We show that EGCG amyloid remodeling activity in vitro is dependent o

247 We show that EGCG binds to the pocket that partly overlaps with the p

248 Here we show that EGCG inhibits the ability of Fap to form fibrils; instea

249 Nanoindentation studies showed that EGCG reduced the stiffness of biofilm containing Fap fib

250 Our data suggest that EGCG intervention does not depend on the individual LC s

251 Collectively, these findings suggest that EGCG regulates ectopic lipid accumulation through a faci

252 in quorum-sensing molecules, suggesting that EGCG interferes with QS through structural remodeling of

253 erved upon EGCG remodeling and suggests that EGCG interferes with secondary nucleation events known t

254 The EGCG treatment resulted in liver failure as evidenced by

255 The EGCG treatment significantly up-regulated renal urea tra

256 nd glutathione systems were activated by the EGCG.

257 -40) oligomers the relative positions of the EGCG B and D rings change with respect to that of ring A

258 as used to verify identity and purity of the EGCG band.

259 we show that sequential self-assembly of the EGCG derivative with anticancer proteins leads to the fo

260 The three aromatic groups of the EGCG molecule are in a stereo (nonplanar) configuration,

261 hanism involving autophagy, the roles of the EGCG-stimulated autophagy in the context of ectopic lipi

262 vitro is dependent on auto-oxidation of the EGCG.

263 nses might render most mice tolerable to the EGCG treatment.

264 a destabilized BBB led to higher therapeutic EGCG concentrations in the brain.

265 Thus EGCG/AA NPs have the potential to be developed as a safe

266 Upon binding to EGCG, the Abeta(1-40) oligomers become less solvent expo

267 tect the lycopene against degradation due to EGCG's anti-oxidant property.

268 tient-derived LC and their susceptibility to EGCG in vitro to probe commonalities and systematic diff

269 bination treatment with EGCG and tobramycin, EGCG had a moderate effect on the minimum bactericidal e

270 e, we evaluate direct application of topical EGCG compared with zonal priming, a unique concept in th

271 Compared to vehicle treatment, EGCG did not significantly improve behavioral performanc

272 1-benzopyran-3-y l 3,4,5-trihydroxybenzoate; EGCG], with metal [Cu(II) and Zn(II)]-Abeta and metal-fr

273 Oxidized and unoxidized EGCG binds to amyloid fibrils, preventing the binding of

274 lains the seeding incompetency observed upon EGCG remodeling and suggests that EGCG interferes with s

275 se xenograft model of prostatic tumor, using EGCG-loaded NPs, with a model of targeted nanosystems, w

276 chins responsible for this preservation were EGCG and C, confirmed by LC-MS.

277 ed the survival rate from 39 to 69%, whereas EGCG had no significant effect.

278 st wild-type P. aeruginosa biofilms, whereas EGCG had a more pronounced effect when Fap was overexpre

279 To determine whether EGCG affects palmitate-induced lipid accumulation, the e

280 Here, we examined whether EGCG can enhance hepatocyte-mediated intracellular innat

281 yocyanin, demonstrating a mechanism by which EGCG can affect the QS function of functional amyloid.

282 n support of the proposed mechanism by which EGCG interactions with the food allergens contribute to

283 nding of the molecular mechanism(s) by which EGCG remodels mature amyloid fibrils made up of Abeta(1-

284 nvestigation, such as the mechanism by which EGCG specifically activates 67LR.

285 While EGCG engages AS in compact conformations, DA preferentia

286 tethered to direct contacts, explaining why EGCG remodeling occurs without release of Abeta(1-40) mo

287 (APP/PS1) mice, a familial model of AD, with EGCG/AA NPs resulted in a marked increase in synapses, a

288 or enrichment of syrups or concentrates with EGCG and for the preparation of enriched beverages and f

289 , treatment of HCV-infected hepatocytes with EGCG and HCV dsRNAs inhibited viral replication.

290 ) concentrations were ca. 5 fold higher with EGCG/AA NPs.

291 ects on AS structure as assessed by IM, with EGCG leading to protein compaction and DA to its extensi

292 M2 macrophages were increased with EGCG compared with placebo.

293 In addition, upon incubation with EGCG, the toxicity presented by metal-free Abeta and met

294 binding sites and similar binding modes with EGCG.

295 ase 5 inhibitor, vardenafil, synergizes with EGCG to induce cancer cell death.

296 y increased when the cells were treated with EGCG and palmitate compared with the cells treated with

297 In a combination treatment with EGCG and tobramycin, EGCG had a moderate effect on the m

298 Treatment with EGCG increased formation of LC3-II and autophagosomes in

299 g free energies as compared to those without EGCG.

300 In this work, EGCG-loaded nanostructured lipid carriers (NLC) function